New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

April 8, 2014Prerna Mewawalla, MDTo address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targ
World medicine November 21,2023
Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

Limited Availability of Non-Caucasian Stem Cell Donors: A Growing Problem?

April 8, 2014Prerna Mewawalla, MDTo address the challenge of the limited availability of stem cell donors in non-Caucasians, it is vital that we increase awareness through more campaigns that are targ
World medicine November 21,2023
Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 24, 2019Onclive TeamTwo doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results
World medicine November 21,2023
Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 24, 2019Onclive TeamTwo doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results
World medicine November 21,2023
Eltrombopag Approved in Europe for Severe Aplastic Anemia

Eltrombopag Approved in Europe for Severe Aplastic Anemia

September 2, 2015Silas InmanThe European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavil
World medicine November 21,2023
Eltrombopag Approved in Europe for Severe Aplastic Anemia

Eltrombopag Approved in Europe for Severe Aplastic Anemia

September 2, 2015Silas InmanThe European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavil
World medicine November 21,2023
Cancer Stem Cells Coming Into Sharper Focus

Cancer Stem Cells Coming Into Sharper Focus

November 11, 2015Jane de Lartigue, PhDParticular progress has been made in the development of small-molecule inhibitors of key signaling pathways that are responsible for the unique characteristics of
World medicine November 21,2023
Cancer Stem Cells Coming Into Sharper Focus

Cancer Stem Cells Coming Into Sharper Focus

November 11, 2015Jane de Lartigue, PhDParticular progress has been made in the development of small-molecule inhibitors of key signaling pathways that are responsible for the unique characteristics of
World medicine November 21,2023
Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14, 2020Jessica HergertKami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges th
World medicine November 21,2023
Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

Tafasitamab/Lenalidomide Combo Induces Impressive Response Rates in Relapsed/Refractory DLBCL

August 14, 2020Jessica HergertKami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges th
World medicine November 21,2023
Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23, 2019Danielle TernyilaChristopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with hi
World medicine November 21,2023
Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

Elevated Levels of ST2 and sC5b-9 Potentially Predictive of Thrombotic Microangiopathy

February 23, 2019Danielle TernyilaChristopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with hi
World medicine November 21,2023
Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

August 14, 2020Jessica HergertPretreatment with the investigational JAK2/FLT3 inhibitor pacritinib prior to allogeneic stem cell transplant was shown to be feasible and safe in patients with primary,
World medicine November 21,2023
Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

Pacritinib Pretreatment Demonstrates Intriguing Interim Findings in Myelofibrosis

August 14, 2020Jessica HergertPretreatment with the investigational JAK2/FLT3 inhibitor pacritinib prior to allogeneic stem cell transplant was shown to be feasible and safe in patients with primary,
World medicine November 21,2023
John Theurer Cancer Center Scientists Develop Web-Based Intervention Addressing Distress in Caregivers of Patients Receiving Stem Cell Transplants

John Theurer Cancer Center Scientists Develop Web-Based Intervention Addressing Distress in Caregivers of Patients Receiving Stem Cell Transplants

August 7, 2017Onclive TeamA group of researchers from several institutions in the US, including John Theurer Cancer Center, studied the development of a new, web-based intervention - Pep-Pal- to provi
World medicine November 21,2023
John Theurer Cancer Center Scientists Develop Web-Based Intervention Addressing Distress in Caregivers of Patients Receiving Stem Cell Transplants

John Theurer Cancer Center Scientists Develop Web-Based Intervention Addressing Distress in Caregivers of Patients Receiving Stem Cell Transplants

August 7, 2017Onclive TeamA group of researchers from several institutions in the US, including John Theurer Cancer Center, studied the development of a new, web-based intervention - Pep-Pal- to provi
World medicine November 21,2023
FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

March 30, 2016Silas InmanThe FDA has approved defibrotide sodium as a treatment for severe hepatic veno-occlusive disease with associated kidney or lung abnormalities following hematopoietic stem cell
World medicine November 21,2023
FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation

March 30, 2016Silas InmanThe FDA has approved defibrotide sodium as a treatment for severe hepatic veno-occlusive disease with associated kidney or lung abnormalities following hematopoietic stem cell
World medicine November 21,2023
Rolling Submission Completed for Daratumumab/Rd in Frontline Transplant-Ineligible Myeloma

Rolling Submission Completed for Daratumumab/Rd in Frontline Transplant-Ineligible Myeloma

March 13, 2019Gina ColumbusJason M. BroderickA supplemental biologics license application has been submitted to the FDA for the approval of daratumumab in combination with lenalidomide and dexamethaso
World medicine November 21,2023
Rolling Submission Completed for Daratumumab/Rd in Frontline Transplant-Ineligible Myeloma

Rolling Submission Completed for Daratumumab/Rd in Frontline Transplant-Ineligible Myeloma

March 13, 2019Gina ColumbusJason M. BroderickA supplemental biologics license application has been submitted to the FDA for the approval of daratumumab in combination with lenalidomide and dexamethaso
World medicine November 21,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com